Display options
Cite
Tanemoto M. Progression of Metabolic Acidosis in Chronic Kidney Disease. Kidney Dis (Basel). 2019;6(1):59-63doi: 10.1159/000502380.
Tanemoto, M. (2020). Progression of Metabolic Acidosis in Chronic Kidney Disease. Kidney diseases (Basel, Switzerland), 6(1), 59-63. https://doi.org/10.1159/000502380
Tanemoto, Masayuki. "Progression of Metabolic Acidosis in Chronic Kidney Disease." Kidney diseases (Basel, Switzerland) vol. 6,1 (2020): 59-63. doi: https://doi.org/10.1159/000502380
Tanemoto M. Progression of Metabolic Acidosis in Chronic Kidney Disease. Kidney Dis (Basel). 2020 Jan;6(1):59-63. doi: 10.1159/000502380. Epub 2019 Oct 18. PMID: 32021875; PMCID: PMC6995968.
Copy Download .nbib Format: NLM
Share it on

Kidney Dis (Basel). 2020 Jan;6(1):59-63. doi: 10.1159/000502380. Epub 2019 Oct 18.

Progression of Metabolic Acidosis in Chronic Kidney Disease.

Kidney diseases (Basel, Switzerland)

Masayuki Tanemoto

Affiliations

  1. Department of Internal Medicine, Shin-Kuki General Hospital, Kuki, Japan.
  2. Division of Nephrology, Department of Internal Medicine, International University of Health and Welfare School of Medicine, Atami, Japan.

PMID: 32021875 PMCID: PMC6995968 DOI: 10.1159/000502380

Abstract

BACKGROUND: Metabolic acidosis, which is classified into either high anion gap type (high-AGMA) or non-anion gap type (non-AGMA), is a common complication in chronic kidney disease (CKD), but its development in CKD is obscure.

METHODS: Records of venous blood gas at a general hospital (2015-2017) were assessed by the physiological approach. Excluding records of primary respiratory disturbances, parameters of high-AGMA and non-AGMA (∆AG and ΔΔ, respectively) were compared with the estimated glomerular filtration rate (eGFR).

RESULTS: ΔAG correlated with eGFR negatively (

CONCLUSION: High-AGMA developed and progressed in CKD stage G5. Non-AGMA generally progressed before the early phase of CKD stage G5 and regressed thereafter.

Copyright © 2019 by S. Karger AG, Basel.

Keywords: Acid-base disorder; Chronic kidney disease; Disease progression; Kidney failure; Metabolic acidosis

Conflict of interest statement

The author has no conflicts of interests to declare.

References

  1. J Am Soc Nephrol. 2009 Sep;20(9):2075-84 - PubMed
  2. Kidney Int. 2012 May;81(10):1033-1042 - PubMed
  3. Am J Kidney Dis. 2016 Feb;67(2):307-17 - PubMed
  4. Arch Intern Med. 1979 Oct;139(10):1099-102 - PubMed
  5. Crit Care Med. 1998 Nov;26(11):1807-10 - PubMed
  6. Adv Chronic Kidney Dis. 2017 Sep;24(5):274-279 - PubMed
  7. Am J Kidney Dis. 1988 Mar;11(3):238-47 - PubMed
  8. Am J Nephrol. 2000 Sep-Oct;20(5):369-72 - PubMed
  9. Kidney Int. 1981 Sep;20(3):416-25 - PubMed
  10. Clin J Am Soc Nephrol. 2013 Nov;8(11):2018-24 - PubMed
  11. Am J Kidney Dis. 2009 Jun;53(6):982-92 - PubMed
  12. J Am Soc Nephrol. 2009 Jan;20(1):164-71 - PubMed
  13. N Engl J Med. 2014 Oct 9;371(15):1434-45 - PubMed
  14. Kidney Int. 2012 Sep;82(6):701-9 - PubMed
  15. J Lab Clin Med. 2005 Dec;146(6):317-20 - PubMed
  16. Kidney Int. 2010 Apr;77(7):617-23 - PubMed
  17. N Engl J Med. 2014 Dec 11;371(24):2309-19 - PubMed

Publication Types